NO963378L - Behandling av antibiotisk assosiert diare - Google Patents

Behandling av antibiotisk assosiert diare

Info

Publication number
NO963378L
NO963378L NO963378A NO963378A NO963378L NO 963378 L NO963378 L NO 963378L NO 963378 A NO963378 A NO 963378A NO 963378 A NO963378 A NO 963378A NO 963378 L NO963378 L NO 963378L
Authority
NO
Norway
Prior art keywords
associated diarrhea
antibiotic
treatment
cdad
relates
Prior art date
Application number
NO963378A
Other languages
English (en)
Norwegian (no)
Other versions
NO963378D0 (no
Inventor
Louis D Heerze
Glen D Armstrong
Original Assignee
Synsorb Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synsorb Biotech Inc filed Critical Synsorb Biotech Inc
Publication of NO963378D0 publication Critical patent/NO963378D0/no
Publication of NO963378L publication Critical patent/NO963378L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ceramic Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO963378A 1994-02-14 1996-08-13 Behandling av antibiotisk assosiert diare NO963378L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/195,009 US5484773A (en) 1994-02-14 1994-02-14 Treatment of antibiotic associated diarrhea
PCT/CA1995/000060 WO1995021628A1 (en) 1994-02-14 1995-02-09 Treatment of antibiotic associated diarrhea

Publications (2)

Publication Number Publication Date
NO963378D0 NO963378D0 (no) 1996-08-13
NO963378L true NO963378L (no) 1996-08-13

Family

ID=22719705

Family Applications (1)

Application Number Title Priority Date Filing Date
NO963378A NO963378L (no) 1994-02-14 1996-08-13 Behandling av antibiotisk assosiert diare

Country Status (15)

Country Link
US (2) US5484773A (de)
EP (1) EP0744959B1 (de)
JP (1) JP4122052B2 (de)
KR (1) KR970701064A (de)
CN (1) CN1131070C (de)
AT (1) ATE267614T1 (de)
AU (1) AU698275B2 (de)
CA (1) CA2181359C (de)
DE (1) DE69533084T2 (de)
IL (1) IL112428A (de)
MX (1) MX197129B (de)
NO (1) NO963378L (de)
NZ (1) NZ279180A (de)
WO (1) WO1995021628A1 (de)
ZA (1) ZA95630B (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2150888T1 (es) * 1991-10-18 2000-12-16 Synsorb Biotech Inc Diagnosis y tratamiento de la disenteria bacteriana.
DE4428056A1 (de) * 1994-07-29 1996-02-08 Schering Ag Verwendung von Mikropartikelpräparationen zur Eliminierung gelöster, nicht nierengängiger Substanzen aus dem Blut
US6140045A (en) * 1995-03-10 2000-10-31 Meso Scale Technologies Multi-array, multi-specific electrochemiluminescence testing
US5627163A (en) * 1995-06-05 1997-05-06 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US5637576A (en) * 1995-06-05 1997-06-10 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US5661131A (en) * 1995-06-05 1997-08-26 Synsorb Biotech, Inc. Treatment of cholera
US5811409A (en) * 1995-06-05 1998-09-22 Synsorb Biotech, Inc. Treatment of cholera
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
US6069137A (en) * 1996-03-11 2000-05-30 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
US5891860A (en) * 1996-03-11 1999-04-06 Synsorb Biotech, Inc. Treatment of traveller's diarrhea
JPH107575A (ja) * 1996-06-21 1998-01-13 Synsorb Biotec Inc 細菌性赤痢の処置
US5846943A (en) * 1996-11-08 1998-12-08 Synsorb Biotech, Inc. Solid support matricles containing a toxin binding oligosaccharide
US6013634A (en) * 1996-11-08 2000-01-11 Synsorb Biotech, Inc. Solid support matrices containing a toxin binding oligosaccharide
US6063769A (en) * 1996-11-14 2000-05-16 Synsorb Biotech, Inc. 1-thiogalactose derivatives
US5932554A (en) * 1996-11-14 1999-08-03 Synsorb Biotech, Inc. 1-galactose derivatives
US5968907A (en) * 1996-11-14 1999-10-19 Synsorb Biotech, Inc. 1-thiogalactose derivatives
US6087339A (en) * 1996-11-14 2000-07-11 Synsorb Biotech, Inc. Saccharide derivatives
JP2001505558A (ja) * 1996-11-15 2001-04-24 シンソーブ バイオテック,インコーポレイテッド 炭化水素ライブラリーのコンビナトリアル合成
US5965719A (en) * 1996-11-15 1999-10-12 Sunsorb Biotech, Inc. Combinatorial synthesis of carbohydrate libraries
US6096725A (en) * 1997-07-02 2000-08-01 Neose Technologies, Inc. Methods of using αGal oligosaccharides as immune system targeting agents
US20020019991A1 (en) * 1998-04-30 2002-02-14 Abbott Laboratories Compositions containing an alpha 1,2-fucose linkage and uses thereof
US6174867B1 (en) 1998-05-08 2001-01-16 Synsorb Biotech, Inc. 1-galactose derivatives having a carbon- or nitrogen-containing aglycon linkage
US6013635A (en) * 1998-05-28 2000-01-11 Synsorb Biotech, Inc. Treatment of C. difficile toxin B associated conditions
US6358930B1 (en) 1998-05-28 2002-03-19 Synsorb Biotech Inc. Treatment of C. difficile toxin B associated conditions
US6291435B1 (en) * 1999-03-04 2001-09-18 The Governs Of The University Of Alberta Treatment of diarrhea caused by enteropathogenic Escherichia coli
US6290946B1 (en) 1999-05-13 2001-09-18 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders and antibacterial agents
US6270755B1 (en) 1999-05-13 2001-08-07 Geltex Pharmaceuticals, Inc. Anionic polymers as toxin binders
CA2314494A1 (en) 2000-05-02 2001-11-02 Geltex Pharmaceuticals, Inc. Anionic polymers as species specific antibacterial agents
US6596707B2 (en) * 2001-05-24 2003-07-22 Abbott Laboratories Monovalent saccharides and uses thereof
NZ537594A (en) * 2002-07-22 2008-05-30 Genzyme Corp Poly (potassium and sodium styrene sulfonate), its manufacture and its uses
US7682631B2 (en) * 2003-10-01 2010-03-23 Clemson University Adhesin-specific nanoparticles and process for using same
WO2005055944A2 (en) * 2003-12-05 2005-06-23 Cincinnati Children's Hospital Medical Center Oligosaccharide compositions and use thereof in the treatment of infection
US20060078534A1 (en) * 2004-10-13 2006-04-13 Dominique Charmot Toxin binding compositions
WO2006044577A1 (en) * 2004-10-13 2006-04-27 Ilypsa, Inc. Pharmaceutical compositions comprising a toxin-binding oligosaccharide and a polymeric particle
CN101257892B (zh) * 2005-05-18 2013-01-02 达沃尔泰拉公司 吸附剂的结肠递送
US7915235B2 (en) * 2006-03-20 2011-03-29 Brian Dieckgraefe High affinity ligands bind to clostridium difficile toxin A
WO2007114683A1 (en) * 2006-03-30 2007-10-11 N.V. Nutricia Milk oligosaccharides for stimulating the immune system
US8048413B2 (en) 2006-05-17 2011-11-01 Helene Huguet Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules
US20080041643A1 (en) * 2006-08-17 2008-02-21 Khalife Tony N Wind-power vehicle aka WPV
MX2010002562A (es) 2007-09-07 2011-04-11 Inst Nac De Ciencias Medicas Y Nutricion Uso de los niveles de antigeno secretor, de lewis y de sialilo como predictores para enfermedad.
JP2012532195A (ja) * 2009-07-06 2012-12-13 チルドレンズ ホスピタル メディカル センター 乳オリゴ糖による炎症の阻害
US10626460B2 (en) 2013-02-21 2020-04-21 Children's Hospital Medical Center Use of glycans and glycosyltransferases for diagnosing/monitoring inflammatory bowel disease
US10857167B2 (en) 2015-04-28 2020-12-08 Children's Hospital Medical Center Use of oligosaccharide compositions to enhance weight gain
CN108977497A (zh) * 2018-06-12 2018-12-11 深圳市领治医学科技有限公司 一种采集和保存人痕量粪便样本的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1544908A (en) * 1975-07-08 1979-04-25 Chembiomed Ltd Artificial oligosaccharide antigenic determinants
US4362720A (en) * 1977-04-14 1982-12-07 Chembiomed Ltd. Synthesis of 2-amino-2-deoxyglycoses and 2-amino-2-deoxyglycosides from glycals
DE2857790C2 (de) * 1977-04-14 1983-12-22 Chembiomed Ltd., Edmonton, Alberta Verfahren zur Herstellung von O-geschützten 2-Azido-2-desoxy-glycosylhalogeniden, einige derartige Verbindungen als solche und deren Verwendung
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US4863852A (en) * 1985-07-03 1989-09-05 Virginia Tech Intellectual Properties, Inc. Method of detecting, isolating and purifying clostridium difficile toxin A and its receptors
US5079353A (en) * 1987-12-02 1992-01-07 Chembiomed, Ltd. Sialic acid glycosides, antigens, immunoadsorbents, and methods for their preparation
US5098826A (en) * 1990-03-09 1992-03-24 Virginia Tech Intellectual Properties, Inc. Detection, isolation and purification of Clostridium difficile toxin A with toxin receptors
US5266315A (en) * 1990-05-07 1993-11-30 Kabushiki Kaisha Miyarisan Seibutsu Igaku Kenkyusho Composite for Clostridium difficile diarrhea and pseudomembranous colitis
ES2150888T1 (es) * 1991-10-18 2000-12-16 Synsorb Biotech Inc Diagnosis y tratamiento de la disenteria bacteriana.

Also Published As

Publication number Publication date
US5484773A (en) 1996-01-16
WO1995021628A1 (en) 1995-08-17
EP0744959B1 (de) 2004-05-26
IL112428A (en) 1999-08-17
DE69533084T2 (de) 2005-06-09
DE69533084D1 (de) 2004-07-01
JP4122052B2 (ja) 2008-07-23
ATE267614T1 (de) 2004-06-15
EP0744959A1 (de) 1996-12-04
US5635606A (en) 1997-06-03
CA2181359A1 (en) 1995-08-17
MX9603403A (es) 1998-10-31
CN1131070C (zh) 2003-12-17
NO963378D0 (no) 1996-08-13
KR970701064A (en) 1997-03-17
ZA95630B (en) 1995-10-05
AU698275B2 (en) 1998-10-29
IL112428A0 (en) 1995-03-30
MX197129B (es) 2000-06-23
AU1572795A (en) 1995-08-29
JPH09508631A (ja) 1997-09-02
CA2181359C (en) 2001-07-03
CN1140415A (zh) 1997-01-15
NZ279180A (en) 1997-10-24

Similar Documents

Publication Publication Date Title
NO963378D0 (no) Behandling av antibiotisk assosiert diare
EP1089740B8 (de) Zusammensetzungen zur behandlung von durch c. difficile toxin b verursachten durchfallerkrankungen (cdad)
ATE155164T1 (de) Lipase und terpen enthaltende waschmittelzusammensetzungen
EP1072270A3 (de) Botulinumtoxine zur Behandlung von Dystonie
EA200000548A1 (ru) Сфероиды, способ получения и фармацевтические композиции
TR199800374A2 (xx) Pestisit bile�imleri.
BG101966A (en) Application of 1l-agonist for the treatment of lack of urine retention
MX9804588A (es) Uso de composiciones que comprenden blanqueador de halogeno para suavidad mejorada a la piel.
DE59712873D1 (de) Halogenpyrimidinylaryl(thio)ether als pestizide
DK1064009T3 (da) Anvendelse af ekstrakter af irisplanter og Cimicifuga racemosa og tectorigenin som estrogenagtigt organselektivt lægemiddel uden uterotrop virkning
GB9003939D0 (en) Sulphatase inhibitors
DK0778890T3 (da) DNA, som koder for en human calciumkanal-alpha-1E-underenhed
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
ZA965731B (en) Clostridium difficile toxins as mucosal adjuvants.
NO943765L (no) Aryloksybenzen-herbicidmidler
TR200000903T2 (tr) Romatizmal arteritlerin tedavisine yönelik yöntem ve kompozisyonlar.
BG104373A (en) Polymorphous forms of dofetilide
FI962979A0 (fi) Hirudiinia sisältävät farmaseuttiset koostumukset
FI943069L (fi) Kloorittomia, mahdollisesti vetypitoisia fluorihiilivetyjä sisältävät koostumukset
MXPA03001986A (es) Composiciones antitromboticas.
DK1015579T3 (da) Clostridiumtoxin samt fremgangsmåde til fremstilling af immunogene sammensætninger
WO2004060856A3 (en) Organic activator
IL119412A (en) Gonadotropins and pharmaceutical compositions containing them
GB8928811D0 (en) An activator for damaged neurocytes for the prevention and treatment of disease
DK0971707T3 (da) Præparater til behandling af forbrændinger og eksterne ulcerationer og en fremgangsmåde til fremstilling deraf

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application